Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 7, Issue 1, 2026

Comparative Analysis of Clinical Efficacy of Different Glaucoma Treatment Regimens

Download as PDF

DOI: 10.23977/medsc.2026.070111 | Downloads: 1 | Views: 31

Author(s)

Tong Xin 1, Su Yang 2

Affiliation(s)

1 Kunming University of Science and Technology, Kunming, 650500, China
2 The First People's Hospital of Yunnan Province, Kunming, 650100, China

Corresponding Author

Tong Xin

ABSTRACT

This study aims to explore the treatment outcomes and related differences among different types of glaucoma. The research selected 45 primary open-angle glaucoma patients (Group A), 45 primary angle-closure glaucoma patients (Group B), and 46 secondary glaucoma patients (Group C) as subjects, and all these patients underwent trabeculectomy. Treatment effectiveness was evaluated based on five aspects: the degree of intraocular pressure (IOP) reduction, the rate of visual field loss progression, changes in optic nerve fiber layer thickness, the incidence of postoperative complications, and patient quality of life scores. Data were processed using statistical methods such as one-way ANOVA. Overall comparisons of IOP reduction, visual field loss progression rate, optic nerve fiber layer thickness changes, and postoperative complication incidence among the three groups showed P values all less than 0.001, which indicates significant statistical differences. Two-tailed comparisons within the groups revealed that Group B had a significantly higher degree of IOP reduction than Groups A and C, while Group C had a higher degree than Group A. Additionally, Group B showed a significantly faster rate of visual field loss progression and thinner optic nerve fiber layers compared to Groups A and C, with Group C having a faster progression rate than Group A. Group B also had a significantly higher incidence of postoperative complications than Groups A and C, and Group C had a higher incidence than Group A. In terms of quality of life scores, comparisons of total NEI-VFQ scores, as well as scores in the visual function, psychological state, and social activity participation dimensions, among the three groups showed P values all less than 0.001; Group B had the lowest scores, and Group A had the highest. There are significant differences in treatment outcomes and quality of life among different types of glaucoma, with primary angle-closure glaucoma being more severe and having a poorer prognosis. Clinically, personalized treatment plans should be developed based on the characteristics of different types of glaucoma.​

KEYWORDS

Small lamellar resection; Primary open-angle glaucoma; Primary angle-closure glaucoma; Secondary glaucoma; Clinical efficacy

CITE THIS PAPER

Tong Xin, Su Yang. Comparative Analysis of Clinical Efficacy of Different Glaucoma Treatment Regimens. MEDS Clinical Medicine (2026). Vol. 7, No.1, 109-123. DOI: http://dx.doi.org/10.23977/medsc.2026.070111.

REFERENCES

[1] Huang W Q, Huang Q R, Li C X. Efficacy analysis of different surgical schemes for the treatment of angle-closure glaucoma combined with cataract [J]. Chinese Practical Medicine, 2025, 20(02):58-61.
[2] Haszcz C A, Gołaszewska K, Żarnowski T, et al. Revolution in glaucoma treatment: a review elucidating canaloplasty and gonioscopy-assisted transluminal trabeculotomy as modern surgical alternatives[J]. Frontiers in Medicine, 2025, 121494391.
[3] Liu J, Liang Y, Tian Y, et al. Unlocking the Untapped Potential of Photoresponsive Dual-Gas Nanomedicine in Glaucoma Therapy[J]. Advanced healthcare materials, 2025, e2404245.
[4] Irkec M, Konstas G A, Holló G, et al. Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents[J]. Expert opinion on investigational drugs, 2025, 34(3):231-243.
[5] Shi F Y. Efficacy analysis of modified scleral tunnel glaucoma valve implantation for refractory glaucoma [J]. Systemic Medicine, 2025, 10(03):44-47.
[6] Yao P, Lu J Y, Yang H T. Efficacy of multioperative treatment for true microphthalmia secondary to Angle-closure glaucoma [J]. Chinese Medical Guide, 2025,23(07):26-30.
[7] Wang M. Analysis of the effect of combined surgery on chronic angle-closure glaucoma and cataract [J]. China Modern Drug Application, 2025, 19(02):48-51.
[8] Umapathi M R, Hliang N T, Min S K A, et al.Characteristics of Eyes with Asymptomatic Primary Angle Closure Glaucoma with Varying Severity of Visual Field Loss at Presentation[J]. Journal of glaucoma, 2025, 34(5):358-364.
[9] Kaiyoor D S, Rengappa R. A comparative study of complications and its management following phaco- trabeculectomy in primary open angle glaucoma, primary angle closure glaucoma and pseudo-exfoliative glaucoma with cataract[J]. Indian Journal of Clinical and Experimental Ophthalmology, 2019, 5(1):121-126.
[10] Lee J E, Park Y D, Park M H, et al. Enlargement of microvascular dropout toward the disc-fovea axis indicates new central visual field defect in glaucoma[J]. Scientific Reports, 2025, 15(1):11052.
[11] Wrześniewska M, Dyda M, Skowron P, et al. Complications after Gonioscopy-Assisted Transluminal Trabeculotomy in glaucoma treatment - literature review[J]. Folia medica Cracoviensia, 2024, 64(2):51-62.
[12] Masaaki Y, Yu Y, Taiki K, et al. Long-Term Surgical Outcomes and Possible Postoperative Complication with Severe Corneal Endothelial Cell Loss After Trabeculectomy for Cytomegalovirus-Associated Anterior Uveitis with Secondary Glaucoma[J]. Ocular immunology and inflammation, 2023, 1-9.
[13] Arenstorff V M M, Ahmadzadeh A, Schmidt S B, et al. Vision-related quality of life in patients with glaucoma before and after trabeculectomy[J]. Acta ophthalmologica, 2024, 102(7):779-789.
[14] Yuxin F, Xiaoming D, Lin C, et al. Combination of Trabeculectomy and Primary Pars Plana Vitrectomy in the Successful Treatment of Angle-Closure Glaucoma with BEST1 Mutations: Self-Controlled Case Series[J]. Ophthalmology and therapy, 2022, 11(6):2271-2284.
[15] Zhu Y, Moksha L, Salowe R, et al. Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds[J]. Biomedicine & pharmacotherapy, 2025, 190118319.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 10848
Visits: 837504

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.